Immatics (IMTX) Shares Outstanding (2019 - 2026)
Immatics (IMTX) posted Shares Outstanding (Entity) of $134.1 million for Q4 2025, up 10.29% sequentially from $121.6 million in Q3 2025, and up 10.3% YoY from $121.6 million in Q4 2024.
Analysis
Immatics (IMTX) Shares Outstanding (2019 - 2026) Analysis & Trends
Immatics has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $134.1 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 10.3% year-over-year to $134.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $134.1 million (up 10.3% YoY) and the FY2025 annual result came in at $134.1 million, up 10.3% from the prior year.
- Shares Outstanding (Entity) climbed to $134.1 million in Q4 2025 per IMTX's latest filing, from $121.6 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $134.1 million in Q4 2025 and troughed at $62.9 million in Q1 2021.
- A 5-year average of $88.6 million and a median of $81.9 million in 2023 frame the typical range for Shares Outstanding (Entity).
- The widest YoY moves for Shares Outstanding (Entity): up 90.09% in 2021, down 0.0% in 2021.
- Over 5 years, Shares Outstanding (Entity) stood at $62.9 million in 2021, then increased by 21.84% to $76.7 million in 2022, then grew by 10.42% to $84.7 million in 2023, then jumped by 43.58% to $121.6 million in 2024, then gained by 10.3% to $134.1 million in 2025.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $134.1 million, $121.6 million, and $121.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | 122.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 122.35 Mn |
| Mar 31, 2026 | 122.35 Mn |
| Dec 31, 2025 | 122.35 Mn |
| Sep 30, 2025 | 105.74 Mn |
| Jun 30, 2025 | 105.74 Mn |
| Mar 31, 2025 | 105.74 Mn |
| Dec 31, 2024 | 105.74 Mn |
| Sep 30, 2024 | 103.11 Mn |
| Jun 30, 2024 | 103.07 Mn |
| Mar 31, 2024 | 98.74 Mn |
| Dec 31, 2023 | 80.55 Mn |
| Sep 30, 2023 | 67.22 Mn |
| Jun 30, 2023 | 67.22 Mn |
| Mar 31, 2023 | 67.22 Mn |
| Dec 31, 2022 | 67.22 Mn |
| Sep 30, 2022 | 62.91 Mn |
| Jun 30, 2022 | 62.91 Mn |
| Mar 31, 2022 | 62.91 Mn |
| Dec 31, 2021 | 62.91 Mn |
| Sep 30, 2021 | 48.00 Mn |